Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes

Karen Barnard1,2, Mary Elizabeth Cox1, Jennifer B Green1,21Department of Medicine, Division of Endocrinology, Diabetes, Metabolism and Nutrition, Duke University Medical Center, Durham, NC, USA; 2Department of Medicine, Division of Endocrinology, Durham Veterans Affairs Medical Center, Durham, NC, U...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Green J, Karen K, Cox ME
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Diabetes mellitus sitagliptin dipeptidyl peptidase-4 combination therapy Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/26c4615e0a4c4f67a75f4a2111c8b728
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:26c4615e0a4c4f67a75f4a2111c8b728
record_format	dspace
spelling	oai:doaj.org-article:26c4615e0a4c4f67a75f4a2111c8b7282021-12-02T01:29:04ZClinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes1178-7007https://doaj.org/article/26c4615e0a4c4f67a75f4a2111c8b7282010-10-01T00:00:00Zhttps://www.dovepress.com/clinical-utility-of-fixed-combinations-of-sitagliptinndashmetformin-in-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Karen Barnard1,2, Mary Elizabeth Cox1, Jennifer B Green1,21Department of Medicine, Division of Endocrinology, Diabetes, Metabolism and Nutrition, Duke University Medical Center, Durham, NC, USA; 2Department of Medicine, Division of Endocrinology, Durham Veterans Affairs Medical Center, Durham, NC, USAAbstract: Adequate glycemic control in type 2 diabetes remains a difficult but achievable goal. The development of new classes of glucose-lowering medications, including in particular the incretin-based therapies, provides an opportunity to utilize combinations of medications which target multiple physiologic abnormalities in type 2 diabetes. Complementary combination therapy with sitagliptin–metformin lowers glucose via enhancement of insulin secretion, suppression of glucagon secretion, and insulin sensitization. Use of this combination in diabetes management will provide a greater degree of glycosylated hemoglobin-lowering than that seen with the use of either drug as monotherapy, is unlikely to cause significant hypoglycemia, and is generally associated with weight loss. The effectiveness, tolerability, and potential cost savings associated with the use of sitagliptin–metformin combination therapy make this an attractive option in diabetes management. The possible beneficial effects of this therapy on beta cell function, as well as its cardiovascular impact, remain inadequately explored but are of significant interest.Keywords: diabetes mellitus, sitagliptin, dipeptidyl peptidase-4, combination therapyGreen JKaren KCox MEDove Medical PressarticleDiabetes mellitussitagliptindipeptidyl peptidase-4combination therapySpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 3, Pp 363-372 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diabetes mellitus sitagliptin dipeptidyl peptidase-4 combination therapy Specialties of internal medicine RC581-951
spellingShingle	Diabetes mellitus sitagliptin dipeptidyl peptidase-4 combination therapy Specialties of internal medicine RC581-951 Green J Karen K Cox ME Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes
description	Karen Barnard1,2, Mary Elizabeth Cox1, Jennifer B Green1,21Department of Medicine, Division of Endocrinology, Diabetes, Metabolism and Nutrition, Duke University Medical Center, Durham, NC, USA; 2Department of Medicine, Division of Endocrinology, Durham Veterans Affairs Medical Center, Durham, NC, USAAbstract: Adequate glycemic control in type 2 diabetes remains a difficult but achievable goal. The development of new classes of glucose-lowering medications, including in particular the incretin-based therapies, provides an opportunity to utilize combinations of medications which target multiple physiologic abnormalities in type 2 diabetes. Complementary combination therapy with sitagliptin–metformin lowers glucose via enhancement of insulin secretion, suppression of glucagon secretion, and insulin sensitization. Use of this combination in diabetes management will provide a greater degree of glycosylated hemoglobin-lowering than that seen with the use of either drug as monotherapy, is unlikely to cause significant hypoglycemia, and is generally associated with weight loss. The effectiveness, tolerability, and potential cost savings associated with the use of sitagliptin–metformin combination therapy make this an attractive option in diabetes management. The possible beneficial effects of this therapy on beta cell function, as well as its cardiovascular impact, remain inadequately explored but are of significant interest.Keywords: diabetes mellitus, sitagliptin, dipeptidyl peptidase-4, combination therapy
format	article
author	Green J Karen K Cox ME
author_facet	Green J Karen K Cox ME
author_sort	Green J
title	Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes
title_short	Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes
title_full	Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes
title_fullStr	Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes
title_full_unstemmed	Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes
title_sort	clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/26c4615e0a4c4f67a75f4a2111c8b728
work_keys_str_mv	AT greenj clinicalutilityoffixedcombinationsofsitagliptinndashmetforminintreatmentoftype2diabetes AT karenk clinicalutilityoffixedcombinationsofsitagliptinndashmetforminintreatmentoftype2diabetes AT coxme clinicalutilityoffixedcombinationsofsitagliptinndashmetforminintreatmentoftype2diabetes
_version_	1718403005019062272

Clinical utility of fixed combinations of sitagliptin&ndash;metformin in treatment of type 2 diabetes

Ejemplares similares

Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes